Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | HPGD | P15428 | 5/20 | 0.65 |
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.65 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.65 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | GGT1 | P19440 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025684 | 0.87 | KDM4E (0.62) | ELANEKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL10483702 | 0.87 | ELANE (1.00) | ELANEKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL21795711 | 0.86 | ELANE (0.63) | ELANEKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL22374226 | 0.86 | KDM4E (0.61) | ELANEKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL14707445 | 0.86 | KDM4E (0.61) | ELANEKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL10483734 | 0.84 | ELANE (1.00) | ELANEKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL29607284 | 0.84 | ELANE (0.74) | ELANEALDH1A1MAPTLMNA | |
| SCHEMBL1914152 | 0.84 | ELANE (0.74) | ELANEKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL29599041 | 0.84 | ELANE (0.74) | ELANEKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL21795728 | 0.83 | ELANE (0.68) | ELANEKDM4EHSD17B10ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104829757-B | A kind of ingredient of solid catalyst of olefin polymerization acid esters compound containing bigcatkin willow and its preparation method and application | 中国科学院化学研究所 | 2018-04-27 | — | — | CN | claimed |
| WO-2021034111-A1 | NOVEL SESQUITERPENE DERIVATIVE AND USE THEREOF | 엠에프씨 주식회사 | 2021-02-25 | — | — | WO | disclosed |
| CN-104829757-B | A kind of ingredient of solid catalyst of olefin polymerization acid esters compound containing bigcatkin willow and its preparation method and application | 中国科学院化学研究所 | 2018-04-27 | — | — | CN | disclosed |
| US-9309233-B2 | Compositions and methods for the treatment of blood clotting disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-12 | — | — | US | disclosed |
| US-9102607-B2 | Peroxide derivatives, their process of preparation and their use in human medicine and in cosmetics for the treatment or prevention of acne | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-08-11 | — | — | US | disclosed |
| US-20150119436-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLOOD CLOTTING DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
| WO-2015021226-A1 | ANALOGS OF VINAXANTHONE AND XANTHOFULVIN, METHODS OF SYNTHESIS, AND METHODS OF TREATMENTS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-02-12 | — | — | WO | disclosed |
| EP-2509944-B1 | NOVEL PEROXIDE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RES & DEV (FR) | 2014-06-18 | — | — | EP | disclosed |
| US-20120323035-A1 | NOVEL PEROXIDE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-12-20 | — | — | US | disclosed |
| EP-2509944-A1 | NOVEL PEROXIDE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | Galderma Research & Development (FR) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011070170-A1 | NOVEL PEROXIDE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-16 | — | — | WO | disclosed |
| EP-1615651-A1 | A PROCESS FOR THE PREPARATION OF FERUTININE FROM FERULA GENUS PLANTS | INDENA S.p.A. (IT) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004087179-A1 | A PROCESS FOR THE PREPARATION OF FERUTININE FROM FERULA GENUS PLANTS | INDENA S.P.A. (IT) | 2004-10-14 | — | — | WO | disclosed |
| US-4006239-A | Benzoic acid amides for mycobacterium infections | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119436-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLOOD CLOTTING DISORDERS | F2, F12, F5 | ELANE 1633/4885KDM4E 4600/4885HSD17B10 524/4885 |
| US-20120323035-A1 | NOVEL PEROXIDE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GPX4, LPO, GPX1 | ELANE 708/4885KDM4E 4061/4885HSD17B10 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.